5 Questions on Preventing, Diagnosing Melanoma

Article

Do you know what factors increase the risk of melanoma? How about the ins and outs of T staging? Test your knowledge on these topics and more in our latest quiz.

 

Question 1:

Answer and Question 2 on Next Page »

The correct answer is: A. Nuclear pleomorphism

 

Question 2:

Answer and Question 3 on Next Page »

The correct answer is: C. Convex shape (the “C” in the ABCDs stands for color-the presence of more than one color or uneven distribution of color)

 

Question 3:

Answer and Question 4 on Next Page »

The correct answer is: B. Reduces the observed rate of melanoma by 50%

 

Question 4:

Answer and Question 5 on Next Page »

The correct answer is: E. All of the above

 

Question 5:

Answer on Next Page »

The correct answer is: D. 81% and 67%

Recent Videos
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content
Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Ibrilatazar Shows Survival Improvement in Advanced Squamous NSCLC

Roman Fabbricatore
June 6th 2025
Article

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Tim Cortese
June 6th 2025
Article

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Gina Mauro
June 5th 2025
Article

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

Ashling Wahner
June 5th 2025
Article

Frontline BNT327/PM8002 plus chemotherapy led to a confirmed ORR of 51.6% and a DCR of 90.3% in patients with unresectable pleural and peritoneal mesothelioma.